Evidence map›Paper›PMID 37201019›Full record

ArticleFrontiers in pharmacology2023

Editorial: Bone and Cartilage Diseases - The Role and Potential of Natural Products, Volume II.

Ming Pei, Daohua Xu, Longhuo Wu

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ming PeiStem Cell and Tissue Engineering Laboratory, Department of Orthopaedics, West Virginia University, Morgantown, WV, United States.
Daohua XuGuangdong Key Laboratory for Research and Development of Natural Drugs, School of Pharmacy, Guangdong Medical University, Dongguan, China.
Longhuo WuCollege of Pharmacy, Gannan Medical University, Ganzhou, China.

Funding

CRISPR-Cas9 Genome Edited MSCs to Target OA Cartilage RegenerationR56AR078846 · NIAMS · WEST VIRGINIA UNIVERSITY · PI PEI, MING · 2022 to 2022
$366k
NIAMS NIH HHS R56 AR078846
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

bone and cartilage diseasesdehydromiltironegenisteinkidney-tonifying Chinese herbsnatural alkaloidsnatural productsosteoporosistraditional Chinese medicine

Identifiers

PMID37201019
PMCPMC10185899

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.